Increased endogenous glucose production (EGP) could contribute to fasting hyperglycaemia in Type II (non-insulin-dependent) diabetes mellitus and could result from increased rates of glycogenolysis or gluconeogenesis (GNG) 
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Abstract Aims/hypothesis. Non-esterified fatty acids and glycerol could stimulate gluconeogenesis and also contribute to regulating hepatic glycogen stores. We examined their effect on liver glycogen breakdown in humans. Methods. After an overnight fast healthy subjects participated in three protocols with lipid/heparin (plasma non-esterified fatty acids: 2.2 0.1 mol/l; plasma glycerol: 0.5 0.03 mol/l; n = 7), glycerol (0.4 0.1 mol/l; 1.5 0.2 mol/l; n = 5) and saline infusion (control; 0.5 0.1 mol/l; 0.2 0.02 mol/l; n = 7). Net rates of glycogen breakdown were calculated from the decrease of liver glycogen within 9 h using 13 C nuclear magnetic resonance spectroscopy. Endogenous glucose production was measured with infusion of D- [6, H 2 ]glucose. Results. Endogenous glucose production decreased by about 25 % during lipid and saline infusion (p < 0.005) but not during glycerol infusion (p < 0.001 vs lipid, saline). An increase of plasma non-esterified fatty acids or glycerol reduced the net glycogen breakdown by about 84 % to 0.6 0.3 mmol´kg ±1´m in ±1 (p < 0.001 vs saline: 3.7 0.5 mmol´kg ±1´m in
±1
) and by about 46 % to 2.0 0.4 mmol´kg ±1´m in ±1 (p < 0.01 vs saline and lipid), respectively. Rates of gluconeogenesis increased to 11.5 0. 8 ), respectively. Conclusion/interpretation: An increase of non-esterified fatty acid leads to a pronounced inhibition of net hepatic glycogen breakdown and increases gluconeogenesis whereas glucose production does not differ from the control condition. We suggest that this effect is not due to increased availability of glycerol alone but rather to lipid-dependent control of hepatic glycogen stores. [Diabetologia (2001) 44 : 48±54] Keywords Non-esterified fatty acids, glycogenolysis, gluconeogenesis, insulin, liver, nuclear magnetic resonance bate. Lipid/heparin infusions increased EGP during somatostatin (SRIF)-insulin clamps [14, 15] but not after an overnight fast [16] . Similarly, nicotinic acid or its derivatives, which inhibit lipolysis, decreased basal EGP in some [17, 18] but not in other studies [19, 20] . Contradictory effects of NEFA on GNG contributing to EGP have also been reported [16,18,20±22] . Differences between these studies are mainly attributed to NEFA-induced insulin secretion counterbalancing a stimulatory effect of NEFA on EGP [15] or to a lipid-associated rise in plasma glycerol, possibly the major gluconeogenic substrate under these conditions, or to both [1] . Finally, NEFA could evoke reciprocal changes of GNG and glycogenolysis which could prevent any increase in EGP [16, 18] .
This study examines the effects of NEFA compared with those of glycerol on net hepatic glycogen breakdown, rates of EGP, and rates of GNG under post-absorptive conditions by combining 
Subjects and methods
Subjects. Seven healthy men (age range: 21±33 years; BMI: 21.7 1.1 kg/m 2 ) without a family history of diabetes mellitus, lipid or bleeding disorders volunteered to ingest a carbohydrate-rich, weight maintaining diet and to refrain from strenuous physical exercise for at least 3 days, then fasted overnight for 12 h before the experiments were carried out. No changes in diet, weight and lifestyle were recorded from the time of recruitment until completion of all studies. All subjects gave their informed, written consent to the protocols which were reviewed and approved by the ethics committee of the University of Vienna Medical School.
Study protocols. At 07:00 hours ( = ±120 min) catheters were inserted in the antecubital veins of the right and left arm of volunteers for blood sampling and infusions and an infusion of d- [6, ) infusion to stepwise increase plasma NEFA concentrations (lipid protocol) and (B) during saline infusion providing control conditions (saline protocol). The procedures were done in a random order. Five subjects were studied again while plasma glycerol concentrations (glycerol protocol) were increased stepwise. All studies were carried out in intervals of 2 to 8 weeks. In all studies blood samples were taken every 90 min, chilled, centrifuged and the supernatants stored at ±20 C until hormones and metabolites were measured.
Analytical procedures. Plasma glucose was measured on a Glucose analyser II (Beckman Instr., Fullerton, Calif.,USA). Plasma NEFA (Wako Chem., Neuss, Germany; intra-assay and inter-assay coefficients of variance CV: 4.3 % and 5.7 %) and glycerol (Boehringer-Mannheim, Mannheim, Germany; CV: 2.0 % and 3.4 %) were quantified enzymatically. Plasma insulin (Pharmacia-Upjohn, Uppsala, Sweden; CV: < 8 %), C peptide (CIS, Gif-Sur-Yvette, France; CV: < 9 %) and glucagon (Serono Diagnostics, Freiburg, Germany; CV: < 8 %) were measured by radioimmunoassay (RIA). Plasma cortisol (CV: < 6 %) was quantified following extraction and charcoaldextran separation by RIA [27].
Gas chromatography-mass spectrometry. Plasma glucose was derivatized to the penta-acetate after Ba(OH) 2 -ZnSO 4 deproteinization and semipurification by anion/cation exchange chromatography (AG1±8X, AG50W-8X; Bio-Rad Laboratories, Richmond, Calif., USA) [24] . The gas chromatography (GC)-mass spectrometry analysis was done on a HewlettPackard 5890 gas chromatograph (HP-1 capillary column, 12 m 0.2 mm 0.33 mm film thickness) interfaced to a Hewlett-Packard 5971A mass selective detector operating in the electron impact ionization mode. For glucose penta-acetate, GC analysis was isothermal at 200 C. Selected ion monitoring was used to quantify enrichments in various molecular ion fragments. The M + 2 enrichment in [6,6- 13 C NMR defines liver glycogen measurements by 13 C nuclear magnetic resonance spectroscopy.
cogen doublet at 100.5 ppm using the same frequency bandwidth for all spectra ( 300 Hz). The absolute quantity of the hepatic glycogen concentration was calculated by comparing the peak integral with that of a glycogen standard obtained under identical conditions. Corrections for loading and sensitive volume of the coil were made.
Liver volume. Liver volumes were measured in a 1.5 T Vision imager (Siemens, Germany) using a body array coil and inphase and post-phase multislice FLASH imaging sequences. Slice number and position was chosen to cover the whole organ. Liver tissue was manually segmented and the area of each region of interest was measured in each slice. Areas were added and multiplied by the sum of slice thickness (0.8 mm) and interslice distance (8 mm).
Calculations and data analysis. Rates of EGP were calculated from the infusion rate of d-[6,6-2 H 2 ]glucose and its enrichment divided by the atom percent enrichment of plasma d-[6,6-2 H 2 ]glucose less the infusion rate. Isotopic steady state was confirmed by repeated measurements of deuterium enrichments in 15 min intervals. Rates of net glycogen breakdown were calculated for each subject from linear regression of the glycogen concentration-time curves of over 9 h. Rates of gluconeogenesis were calculated from the difference between EGP and the net rates of hepatic glycogen breakdown. All data are presented as means SEM. One-way Anova with Bartlett's test for equal variances and post hoc testing by the Bonferroni and the Newman-Keuls test was used for statistical comparisons between and within the different groups. The paired student's t-test was used for statistical comparisons within the time courses of the experiments. Statistical significance of differences was considered at p values of less than 0,05. All calculations were done using the Sigma Stat software package (Jandel Corporation, San Rafael, Calif., USA).
Results
Plasma glucose. Plasma glucose concentrations slowly declined by about 10 % from baseline values until the end of lipid and saline protocols (p < 0.01; Table 1). During glycerol infusion, plasma glucose did not change from baseline and were about 10 % higher than during lipid (p < 0.05) and saline protocols (p < 0.01).
Plasma NEFA and glycerol. Plasma NEFA concentrations rose to about 2.2 mmol/l during lipid/heparin infusion but did not change from baseline values (~0.29 mmol/l) during saline and glycerol protocols (Fig. 2) . Plasma glycerol concentrations were about 0.18 mmol/l at baseline, increased (p < 0.001) about 2.5-fold and about 8-fold during lipid/heparin and glycerol protocols, respectively, but did not change during the saline protocol (Fig. 1) .
Plasma insulin, C peptide, glucagon and cortisol. During the saline and glycerol tests, plasma insulin concentrations decreased continuously until 540 min (p < 0.05) (Fig. 2) . In the last 3 hours of lipid infusion, plasma insulin increased by about 25 % (p < 0.05) above baseline and was about twofold higher than during saline and glycerol infusion at 540 min (p < 0.01). Plasma C peptide concentrations continuously decreased by about 40 % (p < 0.01) and about 30 % (p < 0.05) during saline and glycerol infusion, respectively (Fig. 2) . After 540 min of lipid infusion, plasma C-peptide concentrations had increased by about 30 % (p < 0.05) above baseline (zero time) and were about 2.2-fold higher than during the saline and the glycerol tests (p < 0.001). Plasma glucagon concentrations were similar at baseline and during all experiments (Table 1) . Plasma cortisol decreased (p < 0.05) during glycerol, lipid and saline infusions (Table 1) .
Endogenous glucose production. Rates of EGP were similar in all groups at zero time (Table 1) . Endogenous glucose production showed a similar and contin- uous decline (p < 0.005) during saline and lipid infusion. Only during glycerol infusion, did EGP not change from baseline values and was about 45 % higher (p < 0.001) than during the saline and lipid protocols at 540 min. The mean rates of EGP (0±540 min) were about 20 % higher for the glycerol than for the saline (p < 0.01) and lipid protocols (p < 0.001).
Hepatic glycogen concentrations and net glycogen breakdown. Figure 3A ) during the saline protocol (Fig. 3B) We found that a plasma NEFA increase inhibits the postabsorptive decrease of hepatic glycogen contents so that net glycogen breakdown accounts for only 4 % of EGP. Net hepatic glycogenolysis is also reduced to about 12 % in Type II diabetic [2] and cirrhotic patients [25] , who both have increased plasma NEFA concentrations. Recently, the increase of plasma NEFA was shown by the 2 H 2 O method to increase the contribution of GNG to glucose production [18, 22] . When glycogenolysis was assessed indirectly, glycogenolysis contributed to EGP by about 21 % during the post-acipimox rebound of plasma NEFA to about 1.8 mol/l [18] . In the face of similar plasma NEFA concentrations, it is possible that the higher estimates of glycogenolysis and the lower contribution of GNG to EGP are caused by different plasma NEFA patterns or the effect of acipimox in itself, or both, on hepatic metabolism in their study. More likely, the difference can be explained by the fact that these methods measure different processes [25] . For glycogenolysis, 13 C NMR spectroscopy allows the direct measurement of the actual liver glycogen concentration and the mean rate of net glycogenolysis over the 9-h fasting period. The rate of net gluconeogenesis is therefore also the average for the whole period and is usually calculated using the rates of EGP at the end of that period only. Our study, however, measured EGP repetitively throughout the complete experimental period. These measurements showed only a minor decline from about 14 to about 11 mmol´kg ±1´m in ±1 during lipid and saline infusions. We could therefore use the mean rates of EGP to calculate the contribution of GNG. Nevertheless, using the rates of EGP obtained during the last 3 h would have affected the calculation by only approximately 2 %. The 2 H 2 O method, on the other hand, measures rates of total hepatic glycogenolysis, i. e. net hepatic glycogenolysis + hepatic glycogen cycling. Although glycogen cycling is negligible in the fasting state in healthy subjects [26] , it is relevant under hyperinsulinaemic [26] or hyperglucagonaemic [5] conditions, and might occur during NEFA or glycerol increase or both [33] . Previous studies suggest that NEFA induces reciprocal changes in gluconeogenesis and glycogenolysis, i. e. hepatic autoregulation, resulting in constant EGP [16, 20, 34±37] . In contrast, some authors found that a reduction in plasma NEFA improves suppression of endogenous glucose production [17, 38, 39] ). Recently, the increase in GNG was reported to be less than the decrease in glycogenolysis (~3 vs~4.3 mmol´kg ±1´m in ±1 ) [18] . This could result from underestimating fractional GNG by the C5:C2 ratio to the extent that GNG increases during the course of the study. On the other hand, triose phosphate and pentose cycling as well as transaldolase reactions could each contribute by approximately 2 % to overestimation of GNG from the C5:C2 ratio [40] but they should have no influence on 13 C NMR spectroscopy measurements [25] . Alternatively, NEFA could directly stimulate gluconeogenesis either by supplying the energy necessary for [41] or activating key enzymes of gluconeogenesis like pyruvate carboxylase, or both [42, 43] or phosphoenolpyruvate carboxykinase [44] .
During plasma NEFA increase, plasma insulin and C-peptide concentrations increased in parallel indicating the stimulation of insulin secretion as reported previously in humans [15, 22, 45±48] and in rats [49] . When we consider that portal vein insulin is about 2.5 times the venous insulin and that portal vein contributes about 80 % of the hepatic blood flow, liver sinusoidal insulin concentration was higher during lipid infusion (~83 pmol/l) than during the saline (~50 pmol/l) and glycerol (~53 pmol/l) protocols. Such rise could have affected EGP [50±53] and play a part in restraining glycogenolysis [53] . Furthermore, the rise in insulin concentrations would probably not inhibit hepatic gluconeogenesis thus allowing NEFA to stimulate the process. Moreover, inhibition of hepatic glycogenolysis requires higher insulin concentrations in humans [5, 26, 53] . In addition, portal and also peripheral insulin concentrations are responsible for the hormone's inhibitory effect on the liver [53±55]. Thus, NEFA simultaneously reduces glycogenolysis and increases gluconeogenesis most likely by a direct action, although indirect effects on insulin secretion could also contribute to the effect.
Finally, incrased gluconeogenesis during lipid/heparin infusion could also be the result of increased plasma concentrations [56] or the availability of glycerol, or both [14, 57] ,which is a direct gluconeogenic substrate under these conditions [58, 59] . Plasma glycerol concentrations matching those observed during lipid infusion (~0.48 mmol/l) did not increase gluconeogenesis in healthy subjects [22] . Nevertheless, it cannot be ruled out that in the presence of increased NEFA and insulin, glycerol has some effect which it would not have alone. In this study, high plasma glycerol concentrations increased the rates of GNG to the extent observed during lipid/heparin infusion but were still less effective in reducing net glycogen breakdown. Glycerol-dependent GNG and net glycogen breakdown probably contributed to the higher rates of EGP in the glycerol study, which agrees with a previous study using nicotinic acid [60] . The correlation between plasma glycerol and GNG [61] indicates that the small rise of plasma glycerol concentrations during lipid infusion most likely did not cause the reduction in glycogenolysis. The increase of gluconeogenesis from glycerol in patients with Type II diabetes seems to be a consequence not only of accelerated lipolysis but also of increased intrahepatic conversion of glycerol to glucose [62] .
In conclusion, the rise in plasma NEFA simultaneously inhibits net hepatic glycogen breakdown and gluconeogenesis without affecting endogenous glucose production. This effect is, however, not caused by increased glycerol availability alone, because very high glycerol concentrations were required for a similar increase in gluconeogenesis.
The results therefore suggest that the control of the gluconeogenic rate and the conservation of liver glycogen stores is lipid-dependent in healthy humans. 
